This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication.

Eli Lilly and Co. announced Wednesday that it will boost its investment in Lebanon to more than $13 billion. The move increases Lilly's capital commitment in the United States to more than $23 billion ...

The state of Texas has filed a lawsuit against drug companies that produce insulin and pharmacy benefit managers (PBM), claiming there is a conspiracy to k ...

In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely obese under a phased rollout.

Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...